Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
Background: Regorafenib (REG) is an oral multikinase inhibitor used in colorectal cancer, gastrointestinal stromal tumour and hepatocellular carcinoma. Several adverse events (AEs) are commonly reported during REG administration, and strategies for managing AEs in everyday clinical practice include...
Main Authors: | Alessandro Rizzo, Margherita Nannini, Marco Novelli, Angela Dalia Ricci, Valerio Di Scioscio, Maria Abbondanza Pantaleo |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920936932 |
Similar Items
-
Complete radiological response to first-line regorafenib in a patient with abdominal relapse of mutated GIST
by: Margherita Nannini, et al.
Published: (2020-06-01) -
Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
by: Nakashima, Masayuki
Published: (2021) -
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
by: Wan Wang, et al.
Published: (2019-10-01) -
The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)
by: Alessandro Rizzo, et al.
Published: (2021-02-01) -
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
by: Margherita Nannini, et al.
Published: (2017-12-01)